HTBX Heat Biologics Inc.

7.09
+0.01  (+0%)
Previous Close 7.08
Open 7.25
52 Week Low 1.365
52 Week High 30.1
Market Cap $161,894,740
Shares 22,834,237
Float 22,130,931
Enterprise Value $42,187,267
Volume 892,705
Av. Daily Volume 1,160,257
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
HS-130
Solid tumors
Phase 1
Phase 1
Phase 1 initiation of dosing announced December 16, 2019.
COVID vaccine
COVID-19 vaccine
Phase 1
Phase 1
Phase 1 trial planned.
PTX-35
Solid tumors
Phase 1
Phase 1
Phase 1 initiation of dosing announced June 22, 2020.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2
Phase 2 data presented at ASCO May 29, 2020. Median overall survival (mOS) of 28.7 months.
HS-410
Bladder cancer
Phase 2
Phase 2
Phase 2 trial did not meet primary endpoint - November 30, 2016.

Latest News

  1. DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

    The Heat's presentation will be webcast live at 11:30 a.m. EST on Thursday, January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup

    DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

    The Heat's presentation will be webcast live at 11:30 a.m. EST on Thursday, January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available under the "Investors - News/Events" tab on the Heat Biologics website at www.heatbio.com.

    About Heat Biologics, Inc.

    Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

    Media and Investor Relations Contact

    David Waldman
    +1 919 289 4017

    SOURCE: Heat Biologics, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/624982/Heat-Biologics-CEO-to-Participate-in-a-Fireside-Chat-at-the-B-Riley-Securities-Oncology-Investor-Conference-on-Jan-21-2021

    View Full Article Hide Full Article
  2. DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.

    Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical…

    DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.

    Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials. As previously announced, recent data generated with our collaborators at the University of Miami Miller School of Medicine confirmed ZVX-60 expression of gp96, OX40L and the COVID-19 Spike protein. We believe ZVX-60 holds promise to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches, and look forward to working with Waisman to manufacture ZVX-60 for our first-in-human clinical trial."

    About Heat Biologics, Inc.

    Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

    For more information, please visit: www.heatbio.com, and also follow us on Twitter.

    Forward Looking Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as ZVX-60 holding promise to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches and the gp96 platform activating immune responses against cancer or pathogenic antigens. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of ZVX-60 to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

    Media and Investor Relations Contact

    David Waldman
    +1 919 289 4017

    HEAT BIOLOGICS, INC.
    Consolidated Balance Sheets

    September 30, December 31,
    2020 2019
    (unaudited)
    Current Assets
    Cash and cash equivalents
    $24,808,083 $9,039,887
    Short-term investments
    92,501,019 5,713,922
    Accounts receivable
    212,141 34,986
    Prepaid expenses and other current assets
    1,620,504 420,328
    Total Current Assets
    119,141,747 15,209,123
    Property and Equipment, net
    720,396 559,410
    Other Assets
    In-process R&D
    5,866,000 5,866,000
    Goodwill
    1,452,338 1,452,338
    Operating lease right-of-use asset
    2,123,414 2,287,500
    Finance lease right-of-use asset
    276,918 187,573
    Deposits
    129,505 394,637
    Total Other Assets
    9,848,175 10,188,048
    Total Assets
    $129,710,318 $25,956,581
    Liabilities and Stockholders' Equity
    Current Liabilities
    Accounts payable
    $753,872 $1,503,342
    Deferred revenue, current portion
    1,166,481 3,410,319
    Contingent consideration, current portion
    - 1,124,970
    Contingent consideration, related party - current portion
    - 454,364
    Operating lease liability, current portion
    271,703 216,832
    Finance lease liability, current portion
    106,409 49,104
    Accrued expenses and other liabilities
    1,503,899 1,676,467
    Total Current Liabilities
    3,802,364 8,435,398
    Long Term Liabilities
    Other long-term liabilities
    26,331 -
    Derivative warrant liability
    60,915 -
    Deferred tax liability
    361,911 361,911
    Deferred revenue, net of current portion
    240,000 200,000
    Operating lease liability, net of current portion
    1,374,141 1,519,574
    Financing lease liability, net of current portion
    187,881 142,667
    Contingent consideration, net of current portion
    2,131,830 1,653,197
    Contingent consideration, related party - net of current portion
    626,685 485,984
    Total Liabilities
    8,812,058 12,798,731
    Commitments and Contingencies (Note 13)
    Stockholders' Equity
    Common stock, $.0002 par value; 250,000,000 shares authorized, 157,021,194 and 33,785,999 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
    31,402 6,757
    Additional paid-in capital
    245,740,939 118,173,843
    Accumulated deficit
    (124,195,893) (104,597,748)
    Accumulated other comprehensive loss
    (35,910) (11,250)
    Total Stockholders' Equity - Heat Biologics, Inc.
    121,540,538 13,571,602
    Non-Controlling Interest
    (642,278) (413,752)
    Total Stockholders' Equity
    120,898,260 13,157,850
    Total Liabilities and Stockholders' Equity
    $129,710,318 $25,956,581

    HEAT BIOLOGICS INC.
    Consolidated Statements of Operations and Comprehensive Loss (unaudited)

    Three Months Ended Nine Months Ended
    September 30, September 30,
    2020 2019 2020 2019
    Revenue:
    Grant and contract revenue
    $ 849,732 $ 6,439 $ 2,344,777 $ 1,049,988
    Operating expenses:
    Research and development
    3,172,663 3,129,356 8,745,966 9,725,744
    General and administrative
    6,579,193 1,993,136 11,651,415 7,201,196
    Goodwill impairment loss
    - 737,000 - 737,000
    Change in fair value of contingent consideration
    229,000 502,000 1,045,000 728,290
    Total operating expenses
    9,980,856 6,361,492 21,442,381 18,392,230
    Loss from operations
    (9,131,124) (6,355,053) (19,097,604) (17,342,242)
    Change in fair value of warrant liability
    (37,230) - (1,039,303) -
    Investor relations expense
    - - (66,767) -
    Interest income
    140,614 97,415 249,404 373,060
    Other income (expense), net
    111,307 (73,275) 127,599 (80,539)
    Total non-operating income (loss)
    214,691 24,140 (729,067) 292,521
    Net loss before income taxes
    (8,916,433) (6,330,913) (19,826,671) (17,049,721)
    Income tax expense
    - - - (45,178)
    Net loss
    (8,916,433) (6,330,913) (19,826,671) (17,094,899)
    Net loss - non-controlling interest
    (64,824) (136,315) (228,526) (413,955)
    Net loss attributable to Heat Biologics, Inc.
    $ (8,851,609) $ (6,194,598) $ (19,598,145) $ (16,680,944)
    Net loss per share attributable to Heat Biologics, Inc.-
    Net loss per share attributable to Heat Biologics, Inc.-basic and diluted
    $ (0.06) $ (0.18) $ (0.20) $ (0.50)
    Weighted-average number of common shares used in net loss per share attributable to common stockholders-
    Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted
    143,728,870 33,650,829 96,481,271 33,255,535
    Comprehensive loss:
    Net loss
    $ (8,916,433) $ (6,330,913) $ (19,826,671) $ (17,094,899)
    Unrealized (loss) gain on foreign currency translation
    (63,954) 63,711 (24,660) 72,134
    Total comprehensive loss
    (8,980,387) (6,267,202) (19,851,331) (17,022,765)
    Comprehensive loss attributable to non-controlling interest
    (64,824) (136,315) (228,526) (413,955)
    Comprehensive loss - Heat Biologics, Inc.
    $ (8,915,563) $ (6,130,887) $ (19,622,805) $ (16,608,810)

    SOURCE: Heat Biologics, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/624776/Heat-Biologics-Commences-Manufacturing-Process-for-ZVX-60

    View Full Article Hide Full Article
  3. DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021. Mr. Ostrander has over two decades of experience in financial management at public and private companies and previously served as the Company's Vice President of Finance since joining in September 2019.

    Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "The Board and I have enthusiastically promoted Mr. Ostrander to the role of Chief Financial…

    DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021. Mr. Ostrander has over two decades of experience in financial management at public and private companies and previously served as the Company's Vice President of Finance since joining in September 2019.

    Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "The Board and I have enthusiastically promoted Mr. Ostrander to the role of Chief Financial Officer to reflect the tremendous work that Bill has done to navigate our finances and carefully manage our expenses. Bill's work has helped bring us to a stronger financial position than at any point in the Company's history-with over $117 million in cash and short-term investments at the end of the third quarter of 2020."

    Bill Ostrander, further noted, "It is an honor to serve as Chief Financial Officer of Heat Biologics at this exciting stage in the Company's development. We are well positioned, both operationally and financially, to execute on a number of key milestones in 2021 that we believe will drive significant value for shareholders."

    About Heat Biologics, Inc.

    Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

    For more information, please visit: www.heatbio.com, and also follow us on Twitter.

    Forward Looking Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding being well positioned, both operationally and financially, to execute on a number of key milestones in 2021 that will drive significant value for shareholders. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of execute on a number of key milestones, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

    Media and Investor Relations Contact

    David Waldman
    +1 919 289 4017

    SOURCE: Heat Biologics, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/623735/Heat-Biologics-Promotes-William-L-Ostrander-to-Chief-Financial-Officer

    View Full Article Hide Full Article
  4. DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

    A webcast of Heat's presentation will be available on-demand as of 6:00 am ET, Monday, January 11, 2021, and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of Heat Biologics' website at https://ir.heatbio.com/ir-calendar.

    About Heat Biologics, Inc.

    Heat Biologics is a biopharmaceutical…

    DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

    A webcast of Heat's presentation will be available on-demand as of 6:00 am ET, Monday, January 11, 2021, and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of Heat Biologics' website at https://ir.heatbio.com/ir-calendar.

    About Heat Biologics, Inc.

    Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

    Media and Investor Relations Contact

    David Waldman
    +1 919 289 4017

    SOURCE: Heat Biologics, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/623643/Heat-Biologics-to-Present-at-the-HC-Wainwright-Virtual-BioConnect-2021-Conference

    View Full Article Hide Full Article
  5. Preparations for manufacturing underway

    DURHAM, NC / ACCESSWIRE / December 16, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has completed its gp96-based COVID-19 vaccine cell line ("ZVX-60"), which is being developed for use as either a standalone vaccine, or in combination with other vaccines to enhance prophylactic protection. Data, generated at the University of Miami Miller School of Medicine, has confirmed expression of gp96, OX40L and Spike protein. The Company also reports it has begun preparations for manufacturing…

    Preparations for manufacturing underway

    DURHAM, NC / ACCESSWIRE / December 16, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has completed its gp96-based COVID-19 vaccine cell line ("ZVX-60"), which is being developed for use as either a standalone vaccine, or in combination with other vaccines to enhance prophylactic protection. Data, generated at the University of Miami Miller School of Medicine, has confirmed expression of gp96, OX40L and Spike protein. The Company also reports it has begun preparations for manufacturing, as the next-step towards first-in-human Phase 1 clinical trials.

    Jeff Wolf, Chief Executive Officer of Heat, commented, "We are encouraged by the recent Phase 3 data reported by other vaccine developers, and commend the FDA for their fast action to accelerate approval. Importantly, we believe ZVX-60 holds promise as an adjunct therapy to enhance protection provided by other vaccine approaches. Our preclinical data thus far suggests that our cell line generates a robust T-cell mediated immune response directed against the Spike protein of SARS-CoV-2. Notably, the cell line induced expansion of both "killer" CD8+ T-cells that destroy virus infected cells, as well as "helper" CD4 T-cells that assist in producing anti-viral antibodies."

    "We are also excited to report that preparations for manufacturing the vaccine are well underway. Given the utility and versatility of our vaccine platform, we look forward to advancing ZVX-60 into clinical development."

    About Heat Biologics, Inc.

    Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

    For more information, please visit: www.heatbio.com, and also follow us on Twitter.

    Forward Looking Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding ZVX-60 holding promise as an adjunct therapy to enhance protection provided by other vaccine approaches, the cell line generating a robust T-cell mediated immune response directed against the Spike protein of SARS-CoV-2 and advancing ZVX-60 into clinical development. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat's vaccine platform to enhance protection provided by other vaccine approaches and to provide protection against COVID-19, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

    Media and Investor Relations Contact

    David Waldman
    +1 919 289 4017

    SOURCE: Heat Biologics, Inc.


    View source version on accesswire.com:
    https://www.accesswire.com/621100/Heat-Biologics-Announces-Completion-of-ZVX-60-Vaccine-Cell-Line-for-COVID-19

    View Full Article Hide Full Article
View All Heat Biologics Inc. News